Form 4: CareDx Director Christine Cournoyer Receives RSU Grant
Statement of Changes in Beneficial Ownership
Director Christine Cournoyer was granted 9,795 restricted stock units in CareDx, Inc. as part of standard equity compensation.
Summary
- Director Christine Cournoyer acquired 9,795 restricted stock units (RSUs) of CareDx, Inc. (CDNA) common stock.
- The transaction occurred on June 12, 2026.
- The RSUs were granted at a price of $0 per share.
- Following this transaction, the director's total beneficial ownership is 58,943 shares.
- The grant is subject to a vesting schedule tied to the earlier of the one-year anniversary of the grant or the day before the next Annual Meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standardized RSU grant process indicates normal corporate governance practices.
Negatives
- None identified; this is a routine equity compensation disclosure.
Risks
- Vesting is contingent upon the director's continuous service to the company.
Future Outlook
The RSUs will vest on the earlier of the one-year anniversary of the grant or the day immediately before the first Annual Meeting occurring after the grant date, provided the director maintains continuous service.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology and diagnostics sector to ensure long-term alignment with corporate performance goals.
Comparison to Industry Standards
- The equity grant structure is consistent with standard compensation packages for independent directors at mid-cap healthcare companies.
- Vesting schedules tied to annual meetings are common practice for board members in the U.S. public market.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Authorization of Jeffrey Adam Novack and Colleen Martin-Garcia to file Section 16 reports on behalf of the director. | 07/18/2025 | Administrative update to ensure timely regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard director compensation event.
Next Steps
- Vesting of the 9,795 RSUs on the earlier of the one-year anniversary or the day before the next Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| 07/18/2025 | Date of Power of Attorney execution. |
| 06/12/2026 | Date of the RSU grant transaction. |
| 06/16/2026 | Date of filing. |
Keywords
CareDx, CDNA, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.